Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q35893753)
Watch
English
PD-1/PD-L1 inhibitors.
scientific article published on 2 June 2015
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
review article
1 reference
stated in
Europe PubMed Central
title
PD-1/PD-L1 inhibitors
(English)
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
author
Joel C Sunshine
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
author name string
Janis M Taube
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
publication date
2 June 2015
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
published in
Current Opinion in Pharmacology
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
volume
23
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
page(s)
32-38
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
cites work
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
PD-1 blockade induces responses by inhibiting adaptive immune resistance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Nivolumab in previously untreated melanoma without BRAF mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Mitigating the toxic effects of anticancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Nivolumab plus ipilimumab in advanced melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Expression of programmed death 1 ligands by murine T cells and APC
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
27 July 2018
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
24 September 2018
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
24 September 2018
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
24 September 2018
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
24 September 2018
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4516625
retrieved
24 September 2018
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/26047524
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/26047524
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1016/J.COPH.2015.05.011
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
PMCID
4516625
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
PubMed ID
26047524
1 reference
stated in
Europe PubMed Central
PMCID
4516625
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26047524%20AND%20SRC:MED&resulttype=core&format=json
retrieved
16 February 2020
ResearchGate publication ID
277604865
0 references
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
